Physician profile
Katherine E Funk
NPI 1942884317
$1,949.85
in general payments reported to CMS, 2019-2025
32 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $359 · 2023: $472 · 2024: $557 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $330.38 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $250.44 | 2021-2024 | |
| Pfizer INC. | $179.10 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.62 | 2021-2025 | Xifaxan |
| Dexcom, INC. | $102.85 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $97.18 | 2021-2024 | Farxiga, Breztri |
| Exact Sciences Corporation | $93.98 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $73.55 | 2023-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $61.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.49 | 2021-2022 | |
| Amgen INC. | $51.24 | 2023-2025 | Repatha, Krystexxa |
| Antares Pharma, INC. | $44.67 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Shield Therapeutics INC | $43.36 | 2025 | |
| Novartis Pharmaceuticals Corporation | $40.50 | 2024 | |
| Janssen Pharmaceuticals, INC | $34.52 | 2023 | Xarelto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $32.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.46 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.43 | 2022-2025 | |
| Lilly USA, LLC | $29.41 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Organon LLC | $29.00 | 2024-2025 | Nexplanon |
| Verity Pharmaceuticals INC. | $24.96 | 2024 | Tlando |
| Otsuka America Pharmaceutical, INC. | $23.21 | 2023 | Rexulti |
| Genentech USA, INC. | $21.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.50 | 2024 | Eliquis |
| Sumitomo Pharma America, INC. | $20.46 | 2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $18.51 | 2025 | |
| Lundbeck LLC | $15.97 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $15.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.49 | 2022 | |
| Glaxosmithkline, LLC. | $14.35 | 2024 | Trelegy Ellipta |
| Ars Pharmaceuticals Operations, INC. | $14.23 | 2025 | Neffy |
| Biohaven Pharmaceuticals, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Funk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.